333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 17 000
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Daniel P. O'Day | Chairman & CEO | 7,27M | S.O. | 1964 |
Mr. Andrew D. Dickinson | Executive VP & CFO | 2,94M | S.O. | 1970 |
Ms. Deborah H. Telman | Executive VP of Corporate Affairs, General Counsel & Corporate Secretary | 2,32M | S.O. | 1965 |
Ms. Johanna Mercier | Chief Commercial Officer | 3,32M | S.O. | 1970 |
Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer | 3,07M | S.O. | 1963 |
Ms. Sandra Patterson | Senior VP, Corporate Controller & Principal Accounting Officer | S.O. | S.O. | 1967 |
Ms. Jacquie Ross C.F.A. | Vice President of Investor Relations | S.O. | S.O. | S.O. |
Ms. Jyoti K. Mehra | Executive Vice President of Human Resources | S.O. | S.O. | 1976 |
Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio | S.O. | S.O. | 1962 |
Dr. Rudolf Ertl | Senior Vice President of Commercial Operations of Australia, Canada, Europe | S.O. | S.O. | 1946 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
L’ISS Governance QualityScore de Gilead Sciences, Inc. en date du 1 décembre 2023 est 1. Les scores principaux sont Audit : 3; Société : 4; Droits des actionnaires : 1; Compensation : 3.